Milrinone is an injectable medication primarily used for the short-term treatment of acute decompensated heart failure [1]. It is a phosphodiesterase inhibitor, meaning it works by relaxing the muscles in the heart and blood vessels, which improves the heart's ability to pump blood and widens the blood vessels [1]. This leads to increased cardiac output and reduced blood pressure [1].
What is Milrinone used for?
Milrinone is indicated for the intravenous management of patients with severe symptoms of heart failure who have not responded adequately to conventional therapy [1]. It helps to improve symptoms like shortness of breath and fatigue [1].
Are there Milrinone tablets available?
Currently, milrinone is only available as an injectable solution for intravenous administration. There are no oral tablet formulations of milrinone approved for use.
How does Milrinone work?
Milrinone functions as a selective phosphodiesterase 3 (PDE3) inhibitor [1]. By inhibiting PDE3, it increases intracellular cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle cells [1]. This leads to positive inotropic effects (increased heart muscle contractility) and vasodilatory effects (widening of blood vessels) [1].
What are the side effects of Milrinone?
Common side effects of milrinone include headache, nausea, vomiting, and tremors [1]. More serious adverse effects can involve arrhythmias (irregular heartbeats), hypotension (low blood pressure), and thrombocytopenia (low platelet count) [1].
What is the typical dosage and administration of Milrinone?
Milrinone is administered intravenously, typically as a loading infusion followed by a continuous infusion [1]. The dosage is adjusted based on the patient's response and clinical condition [1].
What is the patent and exclusivity status for Milrinone?
Information regarding the specific patent and exclusivity status for milrinone can be found on DrugPatentWatch.com [2].
Who manufactures Milrinone?
Milrinone is manufactured by several pharmaceutical companies. The specific brand name and manufacturer can vary by region and availability.
How does Milrinone compare to other heart failure treatments?
Milrinone is generally reserved for acute, severe heart failure cases that do not respond to other treatments like diuretics or ACE inhibitors [1]. It is not a long-term oral therapy for chronic heart failure [1]. Other intravenous medications used in acute heart failure include dobutamine and nitroglycerin, which have different mechanisms of action and clinical profiles [1].
What are the risks associated with using Milrinone?
The primary risks of milrinone use are related to its potential to cause arrhythmias, hypotension, and fluid and electrolyte disturbances [1]. Close monitoring of vital signs and cardiac rhythm is crucial during treatment [1].
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK537019/
[2] https://drugpatentwatch.com/